You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1914 Results
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative, Adjuvant
Sep 2017
Regimen
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Jul 2019
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Uterine
Intent: Palliative
Feb 2018
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative
Apr 2016
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Advanced hepatocellular carcinoma, with specific criteria
Mar 2023
Regimen
Cancer Type:
Sarcoma, 
Ewing's
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Aug 2025
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) according to criteria
Sep 2020
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Sep 2020
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Sacituzumab Govitecan - Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
New Drug Funding Program
    Sacituzumab Govitecan - HR-positive HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Jul 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Palliative
Apr 2016

Pages